AN OPEN LABEL PHASE II PHARMACOKINETIC AND PHARMACODYNAMIC ASSESSMENT OF THE POTENTIAL FOR QTC PROLONGATION FOLLOWING FIRST INDUCTION TREATMENT WITH CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME INJECTION IN ACUTE LEUKEMIAS AND MDS PATIENTS: